MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4143/crt.2022.1434

Медицинская библиотека · Cancer research and treatment · 2023

Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404).

Cho Hyungwoo, Yoon Dok Hyun, Shin Dong-Yeop, Koh Youngil, Yoon Sung-Soo, Kim Seok Jin, Do Young Rok, Lee Gyeong-Won, Kwak Jae-Yong, Park Yong, Kim Min Kyoung, Kang Hye Jin, Yi Jun Ho, Yoo Kwai Han, Lee Won Sik, Park Byeong Bae, Jo Jae Cheol, Eom Hyeon-Seok, Kim Hyo Jung, Jeong Seong Hyun, Won Young-Woong, Sohn Byeong Seok, Kwon Ji-Hyun, Suh Cheolwon, Kim Won Seog

Многоцентровое исследованиеСтатьяПеревод в очереди

Аннотация

PURPOSE: We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients.

MATERIALS AND

METHODS

Patients with PTCL receiving chemotherapy with curative intent were registered and prospectively monitored. All patients were pathologically diagnosed with PTCL.

RESULTS

A total of 191 patients with PTCL were enrolled in this prospective registry study. PTCL, not otherwise specified (PTCL-NOS) was the most common pathologic subtype (n=80, 41.9%), followed by angioimmunoblastic T-cell lymphoma (AITL) (n=60, 31.4%). With a median follow-up duration of 3.9 years, the 3-year progression-free survival (PFS) and overall survival (OS) rates were 39.5% and 60.4%, respectively. The role of upfront ASCT was evaluated in patients who were considered transplant-eligible (n=59). ASCT was performed as an upfront consolidative treatment in 32 (54.2%) of these patients. There were no significant differences in PFS and OS between the ASCT and non-ASCT groups for all patients (n=59) and for patients with PTCL-NOS (n=26). However, in patients with AITL, the ASCT group was associated with significantly better PFS than the non-ASCT group, although there was no significant difference in OS.

CONCLUSION

The current study demonstrated that the survival outcomes with the current treatment options remain poor for patients with PTCL-NOS. Upfront ASCT may provide a survival benefit for patients with AITL, but not PTCL-NOS.

Для цитирования: Cho Hyungwoo, Yoon Dok Hyun, Shin Dong-Yeop, Koh Youngil, Yoon Sung-Soo, Kim Seok Jin, Do Young Rok, Lee Gyeong-Won, Kwak Jae-Yong, Park Yong, Kim Min Kyoung, Kang Hye Jin, Yi Jun Ho, Yoo Kwai Han, Lee Won Sik, Park Byeong Bae, Jo Jae Cheol, Eom Hyeon-Seok, Kim Hyo Jung, Jeong Seong Hyun, Won Young-Woong, Sohn Byeong Seok, Kwon Ji-Hyun, Suh Cheolwon, Kim Won Seog. Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404).. Cancer research and treatment. 2023. DOI: 10.4143/crt.2022.1434.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.